The master upstream regulator of the reproductive (HPG) axis, researched for fertility/IVF, hypothalamic amenorrhea and sexual/emotional brain processing.
Research use only — not approved for human therapeutic use by FDA or EMA. An investigational endogenous hormone studied in academic phase 1/2 trials.
Also known as: Kisspeptin-54 (metastin), kisspeptin-10, KISS1 peptide
Binds the GPR54 (KISS1R) receptor on hypothalamic GnRH neurons (Gq/PLC, calcium release), stimulating pulsatile GnRH and downstream LH/FSH and sex hormones. In humans it also enhances sexual and emotional brain processing and reduces sexual aversion — a neuroendocrine 'primer'.
Kisspeptin is the natural upstream trigger of GnRH release. Human studies (notably at Imperial College London) show kisspeptin-54 can trigger oocyte maturation in IVF while sharply reducing ovarian hyperstimulation syndrome risk compared with hCG, thanks to its short (~28-minute) half-life and more physiological LH surge. It has also been used as a diagnostic probe of hypothalamic function and studied in hypothalamic amenorrhea and sexual-brain-response experiments. Evidence remains early: small samples, single-centre, awaiting larger multicentre confirmation.
We report both positive and negative trial results. For exact study protocols, read the sources — we cite them rather than repackage them.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
Generally well tolerated in short trials. Because it acts through the body's own GnRH pathway, reported effects are mild and there is no signal of the hyperstimulation seen with hCG. Long-term and repeated-exposure safety is not established, and continuous high-level exposure can paradoxically desensitise the axis.
GnRH agonists/antagonists and gonadotropins — in the IVF context, where kisspeptin substitutes for the hCG trigger. Conceptually grouped with GnRH itself as the layer upstream of LH/FSH.
Mechanistic context only — we don't publish combinations, amounts or protocols.
Versus hCG as an IVF trigger, kisspeptin-54 produces a shorter, self-limiting LH surge that lowers hyperstimulation risk. Versus GnRH agonists it acts one step further upstream, recruiting endogenous GnRH neurons rather than the pituitary directly.
No. Despite encouraging IVF trial data it is investigational and not FDA/EMA-approved.
Studies show it modulates brain responses linked to attraction, but this is exploratory research, not evidence of a clinical aphrodisiac.
Its very short half-life avoids the prolonged ovarian stimulation that drives hyperstimulation syndrome.
No reviews yet. If you've used Kisspeptin, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.